VRNS · US
VRNS.US: Data security and the AI-feeding surface
Varonis Systems Data security/DSPM: regulation often starts with 'what data may enter a model'. $624M still growing, but the 2026 tape already de-rated the name. Solid theme fit; scale and platfor
Cite a section with a deep link, e.g. /en/r/vrns-us-research#thesis
Snapshot
- Price
- USD 24.7
- Mkt cap
- USD 2.9B
- Revenue
- USD 623.5M
- Revenue YoY (approx)
- 0.1
As-of 2026-09-25 (weekly refresh; equities aligned to §A. Missing series are N/A/null. Not investment advice.)
Thesis
Varonis Systems Data security/DSPM: regulation often starts with 'what data may enter a model'. $624M still growing, but the 2026 tape already de-rated the name. Solid theme fit; scale and platform bundling are the constraints.
Business
Model: data-security subscriptions. Flagships: classification, entitlement tightening, DSPM/cloud data. Edge: unstructured-data depth. Strategy: from on-prem file servers into SaaS/cloud and the AI data plane.
Value chain
Mid-stack data security; upstream storage/SaaS (M365, object storage); downstream security/compliance and data owners. Risks: overlap with Purview and platform DSPM modules; small-cap liquidity.
Valuation
Valuation snapshot (multi-lens)
| Metric | Value | Note |
|---|---|---|
| TTM PE | N/A | 未接入具名行情源;TTM 盈利≤0 或未核验时不填造倍数 |
| PB | N/A | 待最新净资产与市值核验 |
| 股息率 | N/A | 待分红公告 / IR |
| 现价语境 | 约 24.7 | VRNS · 以包内 kpi_snapshot 时点为准 |
Valuation & return · ~3y
Interactive chart available in the reader.
Small/mid security software; sensitive to growth and profit expectations—already de-rated over the past year.
Financial trend (~24 months)
Illustrative 8Q with YoY/QoQ (reconstructed from public disclosures; not audit-line):
Revenue · last 8Q
Interactive chart available in the reader.
Gross margin · last 8Q
Interactive chart available in the reader.
Net income · last 8Q
Interactive chart available in the reader.
Financial health (§A.7)
Financial health (OCF / debt / liquidity / audit)
| Item | Value | Note |
|---|---|---|
| 财务健康总评 | 稳健偏扩张 | 以最新季报 OCF 与净现金为准 |
| 经营现金流 | 见最新 10-Q | AI 周期龙头通常 OCF 强劲 |
| 净负债 / 现金 | 投资级或净现金 | 详见 table 与 IR |
| 流动性 | 充裕 | Current ratio / cash & equivalents |
| 审计意见 | 无保留(常规预期) | 以最新 10-K 为准 |
Operations
Volume: data-estate coverage and cloud customers; price: subscriptions; cost: S&M. OCF typically positive.
Key financials
| Item | Value | YoY | Note |
|---|---|---|---|
| CY2025 rev | ~$624M | +13% | Still growing, not hyper |
| Gross margin | High 80s | — | Software |
| 1Y tape (to 2026-03) | Deep drawdown | — | FA: ~-37% |
| AI hook | Training/feed data control | — | Regulation starts here |
Competition
Peer strengths/weaknesses:
Peer map
| Company | Share/role | Margin | Strength | Weakness |
|---|---|---|---|---|
| Varonis (self) | Data security/DSPM | High GM | Unstructured depth | Scale / bundle risk |
| Palo Alto | Platform DSPM+ | FCF+ | Bundle | Less data-native |
| Microsoft Purview | Compliance suite | N/A | M365 attach | Good enough for many |
| Rubrik | Data resilience | FCF turning | Recovery | Different job |
Management
Management (24m)
| Role | Name | Since | 24m change |
|---|---|---|---|
| CEO | Leadership (see proxy) | ongoing | Verify latest 10-K |
| CFO | CFO office | ongoing | Verify latest proxy |
| Founder influence | Historic founder culture | long | Data-security specialist |
Stability: Specialist management; verify names in latest 10-K; no disclosed control change.
Outlook
Track cloud ARR, overlap with Microsoft/platforms, and contract mix from AI-data use cases.
Scenarios
| Scenario | Condition | Implication |
|---|---|---|
| Bull | Demand/execution beats | Upside |
| Base | Trend continues | Hold/watch |
| Bear | Cycle/competition worsens | Drawdown/reassess |
Risks
Tracking
Observable items that would confirm or falsify this note:
- Cloud ARR growth
- Differentiation vs Purview
- Wins on AI/data-classification use cases
References
Issuer / key sources:
- Latest company filings / IR (see issuer website)
- Exchange filings / SEC EDGAR — https://www.sec.gov/edgar
- Related on-site notes via wiki-links in the body
Not investment advice; defer to latest company filings.
Comments
Sign in to comment